Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 10 tags : Phase 2 save search
Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
Published: 2021-06-10 (Crawled : 21:00) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: 0.12%
H: 1.61%
C: 1.38%
phase 2
Phase 1, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies
Published: 2021-06-10 (Crawled : 20:00) - cytomx.com
CTMX | $1.67 -3.47% -3.59% 510K
|
Health Technology
|
| O: -0.42%
H: 1.25%
C: -0.42%
phase 1 phase 3 phase 2 solid tumors
ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients
Published: 2021-06-10 (Crawled : 13:15) - nantkwest.com
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 0.2%
H: 2.21%
C: -3.24%
phase 2 phase 1 therapy hiv phase 3 injection infections
89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH
Published: 2021-06-10 (Crawled : 13:15) - biospace.com/
ETNB | $9.08 2.25% 2.2% 1M
|
Health Technology
|
| O: 1.06%
H: 2.55%
C: 0.35%
treatment phase 2 phase 2b nash trial
Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer
Published: 2021-06-10 (Crawled : 13:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -0.33%
H: 0.89%
C: -1.0%
treatment phase 2 prostate cancer injection cancer trial hormone enroll
Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC
Published: 2021-06-10 (Crawled : 12:15) - globenewswire.com
CUE | $1.57 -0.63% -0.64% 170K
|
Health Technology
|
| O: 0.84%
H: 3.62%
C: 2.59%
biopharma phase 1 expansion therapy trial phase 3 phase 2
ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021
Published: 2021-06-10 (Crawled : 06:00) - globenewswire.com
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 2.65%
H: 4.19%
C: 1.61%
treatment phase 2 phase 2b
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.